[AZN] Astrazeneca PLC

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NYSE

The data is delayed by 15 minutes.

 

Price: 27.31 Change: 0.14 (0.5%)
Ext. hours: Change: 0 (0%)

chart AZN

Refresh chart

Strongest Trends Summary For AZN

AZN is in the long-term up 39% in 4 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: AstraZeneca PLC is engaged in the discovery, development, and commercialization of medicines for cardiovascular and metabolic disease; oncology; respiratory, inflammation, and autoimmunity; and infection, neuroscience, and gastrointestinal disease areas worldwide. Its principal products include Crestor for the treatment of dyslipidaemia and hypercholesterolemia; Seloken/Toprol-XL for control of hypertension and for use in heart failure and angina; Iressa for non-small cell lung cancer; Faslodex for breast cancer in post-menopausal women; and Zoladex for prostate cancer, breast cancer, and certain benign gynaecological disorders. The company's principal products also comprise Pulmicort for treating asthma and chronic obstructive pulmonary disease (COPD); Symbicort for maintenance treatment of asthma and COPD; Nexium for treatment of acid-related diseases; Seroquel XR for the treatment of schizophrenia, bipolar disorder, major depressive disorder, and generalised anxiety disorder; and Synagis for the prevention

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS3.52 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y156.85% Sales Growth - 4 Quarters Sales Growth - Q/Q P/E9.81
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA ROE ROI
Current Ratio Quick Ratio Long Term Debt/Equity Debt Ratio
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities-2.39 B Cash From Investing Activities-1.23 B Cash From Operating Activities1.01 B Gross Profit5.3 B
Net Profit697 M Operating Profit923 M Total Assets55.17 B Total Current Assets13.81 B
Total Current Liabilities16.15 B Total Debt11.01 B Total Liabilities36.89 B Total Revenue6.31 B
Technical Data
High 52 week43.02 Low 52 week32.97 Last close37.78 Last change-0.05%
RSI45.85 Average true range0.63 Beta0.64 Volume2.88 M
Simple moving average 20 days-0.78% Simple moving average 50 days-5.71% Simple moving average 200 days-2.2%
Performance Data
Performance Week0.35% Performance Month-2.55% Performance Quart-5.56% Performance Half0.08%
Performance Year11.61% Performance Year-to-date-5.24% Volatility daily1.11% Volatility weekly2.47%
Volatility monthly5.07% Volatility yearly17.55% Relative Volume389.21% Average Volume5.47 M
New High New Low

News

2019-12-11 08:00:00 | [Fam]-Trastuzumab Deruxtecan Achieved a Tumor Response of 60.9% in Pivotal Phase II HER2-positive Metastatic Breast Cancer Trial

2019-12-07 07:50:00 | CALQUENCE Significantly Prolonged the Time Patients Lived Without Disease Progression or Death in Previously Untreated Chronic Lymphocytic Leukemia

2019-12-07 03:50:31 | Does AstraZeneca PLC's LON:AZN CEO Salary Reflect Performance?

2019-12-06 16:10:21 | Is AstraZeneca plc AZN Going to Burn These Hedge Funds?

2019-12-06 09:27:02 | Pharma Stock Roundup: FDA Updates for RHHBY, AZN, MRK, No Asbestos in Talc Says JNJ

2019-12-06 09:22:02 | AstraZeneca's Lynparza Gets China Nod in First-Line Setting

2019-12-05 13:01:17 | The biggest deals and attempted deals of the 2010s 

2019-12-05 08:51:01 | Aurinia's Lupus Candidate Succeeds in Pivotal Study, Stock Up

2019-12-05 02:11:48 | REFILE-AstraZeneca-Merck Lynparza wins approval in China for ovarian cancer treatment

2019-12-04 10:41:03 | Immunomedics Resubmits Application for Breast Cancer Drug

2019-12-04 10:25:03 | Biogen's Lupus Candidate Meets Endpoint in Phase II Study

2019-12-04 10:10:03 | AstraZeneca Sells Schizophrenia Drug Rights in US and Canada

2019-12-04 09:22:02 | Roche's Tecentriq-Chemo Combo Gets FDA Nod in First-Line NSCLC

2019-12-04 05:00:00 | Money in Medicine: These drug and device companies paid the most to D.C. doctors in 2018?

2019-12-02 08:30:34 | AstraZeneca's AZN Imfinzi Gets FDA Priority Tag for SCLC

2019-11-30 10:47:36 | China to use drug bulk-buy program to close price gap

2019-11-29 08:48:00 | China Negotiates Bargain Prices With Big Pharma

2019-11-29 03:16:13 | UPDATE 1-AstraZeneca's Imfinzi gets speedy FDA review for small cell lung cancer

2019-11-29 02:32:56 | RPT-AstraZeneca's Imfinzi gets FDA priority review for small cell lung cancer

2019-11-28 08:44:01 | Here's Why Merck's MRK Shares Are Up This Year

2019-11-23 23:02:26 | Here is The 14th Most Popular Stock Among 752 Hedge Funds

2019-11-22 15:39:41 | AstraZeneca CEO: Closing In On A Cancer Cure

2019-11-22 10:57:03 | Pharma Stock Roundup: FDA Nod to NVS' & AZN's Drugs, BMY-CELG Merger Closes

2019-11-22 10:08:01 | AstraZeneca shares rise on early U.S. approval for leukemia drug

2019-11-22 08:36:01 | AstraZeneca Gets FDA Nod for Calquence Line Extension in CLL

2019-11-21 14:54:00 | CALQUENCE Approved in the US for Adult Patients With Chronic Lymphocytic Leukemia

2019-11-21 08:23:01 | Amarin's Shares Down on Underperform Rating by Oppenheimer

2019-11-20 09:30:02 | Alkermes Submits NDA to FDA for Schizophrenia & Bipolar I Drug

2019-11-20 05:30:10 | BT will continue working with skills group if it drops Prince Andrew as patron

2019-11-18 09:34:02 | Roche Gets CHMP Opinion for Breast Cancer & Lymphoma Drugs

2019-11-18 07:46:12 | Here's Why AstraZeneca's AZN Shares Are Up Year to Date

2019-11-17 11:47:00 |  Subgroup Analysis of TWILIGHT Trial Patients With Non-ST Elevation Acute Coronary Syndrome NSTE-ACS Who Underwent PCI Showed BRILINTA Monotherapy Reduced the Risk of Clinically Relevant Bleeding Compared With Dual Antiplatelet Therapy DAPT

2019-11-17 10:45:00 | Consistent Effects of FARXIGA in Heart Failure Patients With Reduced Ejection Fraction Shown in New Analyses From Landmark Phase III DAPA-HF Trial

2019-11-15 09:23:02 | AstraZeneca/Merck's Selumetinib NDA Gets FDA Priority Status

2019-11-15 07:12:12 | Pharma Stock Roundup: MRK, GSK, ABBV, LLY's Pipeline & Regulatory Updates

2019-11-14 10:04:03 | Glaxo's Nucala Meets Goal in Rare Inflammatory Disorder Study

2019-11-14 08:00:00 | AstraZeneca Launches Diabetes Can Break Your Heart

2019-11-13 14:32:17 | Ex-Novartis exec named as Flagship's ‘matchmaker’ for Big Pharma partnerships

2019-11-13 13:14:06 | AVEO Pharmaceuticals AVEO Q3 Earnings & Revenues Top Mark

2019-11-13 10:03:03 | Inovio's INO Q3 Loss In Line, Sales Lag, VGX-3100 in Focus

2019-11-12 08:00:00 | Aravive and AstraZeneca Announce Initiation of Randomized Phase 1/2 Study of AVB-500 in Combination with Durvalumab in Patients with Platinum-Resistant Recurrent Epithelial Ovarian Cancer

2019-11-11 16:23:09 | Pfizer-Merck KGaA's Bavencio Fails in 2nd Gastric Cancer Study

2019-11-11 11:00:01 | AstraZeneca succeeds in treating lupus in late-stage study

2019-11-11 02:57:05 | 10 Stocks Poised for 'Blockbuster' Growth on Surging Sales

2019-11-11 02:42:43 | Don't Sell AstraZeneca PLC LON:AZN Before You Read This

2019-11-09 16:43:11 | Bulls And Bears Of The Week: Roku, Tesla, Twitter, Uber And More

2019-11-08 14:52:45 | UPDATE 1-Safety data on AstraZeneca anaemia drug points to potential use in dialysis

2019-11-08 14:02:00 | Roxadustat Phase III Program Pooled Analyses Showed Positive Efficacy and No Increased Cardiovascular Risk in Patients with Anemia from Chronic Kidney Disease Versus Comparators

2019-11-08 14:00:00 | New Data From the Phase III DAPA-HF Trial Showed FARXIGA Reduced the Worsening of Heart Failure or Cardiovascular Death in HFrEF Patients With and Without Chronic Kidney Disease

2019-11-08 09:26:02 | Pharma Stock Roundup: AGN, NVO Q3 Earnings, FDA Nod to SNY & NVS' Products